Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIORITY: Emicizumab +/- FVIII in Hemophilia A Post-ITI
NCT04621916Phase 4Unknown
- Sponsor
- Children's Hospital Los Angeles
- Start
- Sep 2020
- Primary completion
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Factor VIII in hemophilia A (2 arms), sponsored by Children's Hospital Los Angeles. Primary endpoint: Inhibitor recurrence at 2 years. Status: unknown.
02
Drugs
Factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04621916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04621916.